A double-blind, placebo-controlled, dose-titration study to determine safety, tolerability and preliminary efficacy of RWJ-333369 [carisbamate] as adjunctive therapy in subjects with treatment-resistant partial seizures (with or without secondary generalization) or primarily generalized tonic-clonic seizures

Trial Profile

A double-blind, placebo-controlled, dose-titration study to determine safety, tolerability and preliminary efficacy of RWJ-333369 [carisbamate] as adjunctive therapy in subjects with treatment-resistant partial seizures (with or without secondary generalization) or primarily generalized tonic-clonic seizures

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Dec 2012

At a glance

  • Drugs Carisbamate (Primary)
  • Indications Partial epilepsies; Tonic-clonic epilepsy
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Jun 2012 Company added in association field as reported by ClinicalTrials.gov.
    • 09 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Sep 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top